Stock Events

Stock Events

AbCellera Biologics 

$11.85
626
+$0.73+6.56% 19:00 Today

Statistics

Day High
12.02
Day Low
11.47
52W High
12.02
52W Low
2.75
Volume
8,396,390
Avg. Volume
8,141,037
Mkt Cap
3.63B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.19
-0.14
-0.08
-0.03
Expected EPS
-0.1725
Actual EPS
N/A

Financials

-194.88%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
75.13MRevenue
-146.41MNet Income

Analyst Ratings

16.00Average Price Target
The highest estimate is 30.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABCL. It's not an investment recommendation.
Amazon
107
AMZN
NVIDIA
102
NVDA
Microsoft
98
MSFT
Palantir Technologies
89
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals competes in the discovery, development, and commercialization of treatments for serious medical conditions, similar to AbCellera's focus on antibody therapies.
Adaptive Biotechnologies
ADPT
Mkt Cap3.94B
Adaptive Biotechnologies offers immune-driven medicine solutions, directly competing with AbCellera's antibody discovery for therapeutic use.
Novavax
NVAX
Mkt Cap1.33B
Novavax is involved in the development of vaccines and therapeutics, which overlaps with AbCellera's work on antibody therapies for infectious diseases.
Moderna
MRNA
Mkt Cap25.28B
Moderna is known for its mRNA technology but also competes in the broader biotech space, including therapeutic antibodies, similar to AbCellera.
BioNTech
BNTX
Mkt Cap23.38B
BioNTech SE, while famous for its COVID-19 vaccine, also works on novel therapeutics, including antibodies, making it a competitor.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is engaged in gene editing, a cutting-edge area of biotech that could compete with antibody-based therapies offered by AbCellera.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals focuses on creating new therapies for serious diseases, a mission that aligns with AbCellera's, making them competitors in the biotech space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, a novel approach that could rival AbCellera's antibody-based treatments.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotechnology giant with a broad portfolio that includes antibody therapeutics, making it a competitor across several of AbCellera's areas of interest.

About

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Show more...
CEO
Carl Hansen
Employees
562
Country
Canada
ISIN
CA00288U1066
WKN
000A2QKXS

Listings

MU
DE
8QQ.MU
STU
DE
8QQ.STU
XNAS
US
ABCL
F
DE
8QQ.F

0 Comments

Share your thoughts

FAQ

What is AbCellera Biologics stock price today?▼
The current price of ABCL is $11.85 USD — it has increased by +6.56% in the past 24 hours. Watch AbCellera Biologics stock price performance more closely on the chart.
What is AbCellera Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange AbCellera Biologics stocks are traded under the ticker ABCL.
Is AbCellera Biologics stock price growing?▼
ABCL stock has risen by +13.81% compared to the previous week, the month change is a +82.29% rise, over the last year AbCellera Biologics has showed a +174.71% increase.
What is AbCellera Biologics market cap?▼
Today AbCellera Biologics has the market capitalization of 3.63B
When is the next AbCellera Biologics earnings date?▼
AbCellera Biologics is going to release the next earnings report on November 10, 2026.
What were AbCellera Biologics earnings last quarter?▼
ABCL earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.16 USD resulting in a -9.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is AbCellera Biologics revenue for the last year?▼
AbCellera Biologics revenue for the last year amounts to 75.13M USD.
What is AbCellera Biologics net income for the last year?▼
ABCL net income for the last year is -146.41M USD.
How many employees does AbCellera Biologics have?▼
As of August 19, 2026, the company has 562 employees.
In which sector is AbCellera Biologics located?▼
AbCellera Biologics operates in the Health & Wellness sector.
When did AbCellera Biologics complete a stock split?▼
AbCellera Biologics has not had any recent stock splits.
Where is AbCellera Biologics headquartered?▼
AbCellera Biologics is headquartered in VANCOUVER, Canada.